Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on August 27, 2019, reporting on the closing of its significant collaboration with Galapagos NV, a biopharmaceutical company focused on developing small molecule drugs. This filing confirms the completion of the previously announced collaboration agreement, effective August 23, 2019, which involves significant equity investment and research and development partnerships. Investors should note this move as a strategic step for Gilead to expand its pipeline, particularly in areas of high unmet medical need, leveraging Galapagos' innovative drug discovery platform. The report details Gilead's subsidiary, Gilead Therapeutics A1 Unlimited Company, completing the purchase of 6,828,985 ordinary shares of Galapagos. This transaction brings Gilead's aggregate ownership in Galapagos to 20.1% on a fully diluted basis, underscoring a substantial commitment to the partnership. This collaboration is a key development for Gilead, aiming to enhance its long-term growth prospects through access to novel therapeutic candidates and potentially diversify its revenue streams.
Key Highlights
- 1Gilead Sciences (GILD) closed its previously announced collaboration agreement with Galapagos NV on August 23, 2019.
- 2The closing of the collaboration is pursuant to the Option, License and Collaboration Agreement dated July 14, 2019.
- 3Gilead's Irish subsidiary, Gilead Therapeutics A1 Unlimited Company, purchased 6,828,985 ordinary shares of Galapagos.
- 4The purchase price per Galapagos share was EUR 140.59.
- 5This investment brings Gilead's aggregate ownership in Galapagos to 20.1% on a fully diluted basis (approximately 22.0% of issued and outstanding shares).
- 6The transaction details were previously described in Gilead's Form 8-K filed on July 18, 2019.
- 7The filing includes a joint press release from Gilead and Galapagos as an exhibit.